Aprogen Pharmaceuticals Inc Working Capital to Net Assets Ratio
Aprogen Pharmaceuticals Inc working capital to net assets ratio. Aprogen Pharmaceuticals Inc (003060) has a Working Capital to Net Assets ratio of -9.7% as of September 2025. Working capital of ₩-30.43 Billion (current assets of ₩181.01 Billion minus current liabilities of ₩211.44 Billion) is measured against net assets of ₩315.16 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 003060 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Aprogen Pharmaceuticals Inc (2013–2024)
Working capital to net assets ratio of Aprogen Pharmaceuticals Inc from 2013 to 2024. This chart shows how Aprogen Pharmaceuticals Inc's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the ratio stands at -9.7%, reflecting working capital of ₩-30.43 Billion against net assets of ₩315.16 Billion KRW. See 003060 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Aprogen Pharmaceuticals Inc Working Capital to Net Assets Ratio by Year (2013–2024)
Aprogen Pharmaceuticals Inc working capital to net assets ratio by year from 2013 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Aprogen Pharmaceuticals Inc from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Aprogen Pharmaceuticals Inc (003060) total assets.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -8.5% | ₩-32.31 Billion | ₩378.69 Billion | ₩115.20 Billion | ₩147.51 Billion | ▲ +11.3 pp |
| 2023 | -19.8% | ₩-73.08 Billion | ₩368.69 Billion | ₩84.86 Billion | ₩157.94 Billion | ▼ -35.4 pp |
| 2022 | 15.6% | ₩79.50 Billion | ₩510.41 Billion | ₩240.61 Billion | ₩161.11 Billion | ▼ -42.0 pp |
| 2021 | 57.6% | ₩344.03 Billion | ₩597.18 Billion | ₩353.47 Billion | ₩9.45 Billion | ▲ +2.8 pp |
| 2020 | 54.8% | ₩327.85 Billion | ₩598.36 Billion | ₩336.52 Billion | ₩8.67 Billion | ▲ +1.6 pp |
| 2019 | 53.2% | ₩184.78 Billion | ₩347.64 Billion | ₩195.59 Billion | ₩10.81 Billion | ▲ +36.4 pp |
| 2018 | 16.8% | ₩25.24 Billion | ₩150.51 Billion | ₩87.29 Billion | ₩62.04 Billion | ▼ -24.4 pp |
| 2017 | 41.1% | ₩32.04 Billion | ₩77.86 Billion | ₩66.01 Billion | ₩33.97 Billion | ▼ -7.4 pp |
| 2016 | 48.5% | ₩37.92 Billion | ₩78.12 Billion | ₩83.07 Billion | ₩45.15 Billion | ▼ -9.4 pp |
| 2015 | 57.9% | ₩39.25 Billion | ₩67.75 Billion | ₩49.14 Billion | ₩9.89 Billion | ▼ -3.5 pp |
| 2014 | 61.5% | ₩38.18 Billion | ₩62.11 Billion | ₩48.58 Billion | ₩10.40 Billion | ▲ +1.6 pp |
| 2013 | 59.9% | ₩33.86 Billion | ₩56.55 Billion | ₩43.40 Billion | ₩9.54 Billion | — |